Koster Ad, Tromp Hedwig A, Raemaekers John M M, Borm George F, Hebeda Konnie, Mackenzie Marius A, van Krieken Joannes H J M
Department of Haematology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Haematologica. 2007 Feb;92(2):184-90. doi: 10.3324/haematol.10384.
In follicular lymphoma histological grading is used to predict clinical behavior and to stratify patients for treatment. However, the reproducibility of histological grading is poor and the clinical significance of the difference between grade 1 and grade 2 follicular lymphoma is unclear. Data on proliferation characteristics with respect to prognosis in follicular lymphoma are inconsistent.
We assessed the Proliferation Index in follicles, using Mib-1 immunohistochemical staining in lymph node biopsies from 51 patients with follicular lymphoma who were receiving uniform first-line treatment consisting of cyclophosphamide, vincristine, prednisone and interferon alpha2b.
The median Proliferation Index was 16.9 (range 3.1-49.2). In grades 1 and 2 follicular lymphoma (n=45) it was 16.1, compared to 24.2 in grade 3 (n=6; p=0.02). At a median follow-up of 71 months, patients with a Proliferation Index below the median had a significantly prolonged time to progression (median not reached vs. 15 months for those with a Proliferation Index above the median; p=0.0006) and improved overall survival (median not reached vs. 42 months, respectively; p=0.002). In multivariate analysis, the Proliferation Index retained its predictive value. Additional prognostic information was especially provided in patients with a low International Prognostic Index. Histological grade did not predict outcome.
The Proliferation Index is a biological marker that is strongly and independently predictive for outcome in follicular lymphoma, as shown even in this relatively small series of patients. It is easily applicable and reproducible and therefore superior to histological grading in identifying clinically aggressive follicular lymphoma, requiring other types of treatment.
在滤泡性淋巴瘤中,组织学分级用于预测临床行为并对患者进行治疗分层。然而,组织学分级的可重复性较差,1级和2级滤泡性淋巴瘤之间差异的临床意义尚不清楚。关于滤泡性淋巴瘤增殖特征与预后的数据并不一致。
我们使用Mib-1免疫组化染色评估了51例接受由环磷酰胺、长春新碱、泼尼松和α2b干扰素组成的统一一线治疗的滤泡性淋巴瘤患者淋巴结活检标本中滤泡的增殖指数。
增殖指数中位数为16.9(范围3.1 - 49.2)。在1级和2级滤泡性淋巴瘤(n = 45)中为16.1,而在3级(n = 6)中为24.2(p = 0.02)。中位随访71个月时,增殖指数低于中位数的患者疾病进展时间显著延长(中位数未达到,而增殖指数高于中位数的患者为15个月;p = 0.0006),总生存期也有所改善(分别为中位数未达到和42个月;p = 0.002)。在多变量分析中,增殖指数保留了其预测价值。国际预后指数低的患者尤其获得了额外的预后信息。组织学分级不能预测预后。
增殖指数是一种生物学标志物,即使在这一相对较小的患者系列中也显示出对滤泡性淋巴瘤预后具有强大且独立的预测作用。它易于应用且可重复,因此在识别临床上侵袭性滤泡性淋巴瘤(需要其他类型治疗)方面优于组织学分级。